AR077033A1 - Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas - Google Patents

Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas

Info

Publication number
AR077033A1
AR077033A1 ARP100102023A ARP100102023A AR077033A1 AR 077033 A1 AR077033 A1 AR 077033A1 AR P100102023 A ARP100102023 A AR P100102023A AR P100102023 A ARP100102023 A AR P100102023A AR 077033 A1 AR077033 A1 AR 077033A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
optionally substituted
link
independently
Prior art date
Application number
ARP100102023A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR077033A1 publication Critical patent/AR077033A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Una composicion farmacéutica que incluye un compuesto de la formula 1 y métodos para el uso del mismo. Reivindicacion 1: Un compuesto de la formula (1): los estereoisomeros o las sales farmacéuticamente aceptables del mismo, en la que: A es CR3 o N; B y D son con independencia CR15 o N, dichos B y D no pueden ser N al mismo tiempo; R1 es con independencia H, halogeno, alquilo C1-3, cicloalquilo C3-4, -CF3, -OR6, -SR6, -OCF3, -CN, -NO2, -NR6SO2R7, -NR6C(O)R7 o -NR6R7, en la que dos R1 no pueden ser H al mismo tiempo y dichos alquilo y cicloalquilo están opcionalmente sustituidos por halogeno, OR6, -NR6R7 o fenilo; R2 y R3 son con independencia H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, -(alquilo C0-3)CN, -(alquilo C0-3)OR8, -(alquilo C0-3)SR8, -(alquilo C0-3)NR8R9, -(alquilo C0-3)CF3, -O(alquilo C0-3)CF3, -(alquilo C0-3)NO2, -(alquilo C0-3)C(O)R8, -(alquilo C0-3)C(O)OR8, -(alquilo C0-3)C(O)NR8R9, -(alquilo C0-3)NR8C(O)R9, -(alquilo C0-3)S(O)1-2R8, -(alquilo C0-3)NR8S-(O)1-2R9, -(alquilo C0-3)S-(O)1-2NR8R9, -(alquilo C0-3)(cicloalquilo C3-6), -(alquilo C0-3) (heterociclilo de 3-6 eslabones), -(alquilo C0-3)-(heteroarilo de 5-6 eslabones) o -(alquilo C0-3)fenilo, en la que y R3 están opcionalmente sustituidos con independencia por R10; R4 es H, -NH2, -NH-, -OH, -SH, -NR6C(O)-, -NR6C(O)O-, -NR6C(O)NR7-, -NR6S(O)1-2- o -NR6S(O)1-2NR7-. R5 está ausente, es alquilo C1-6, cicloalquilo C3-6, fenilo, heterociclilo de 3-7 eslabones o heteroarilo de 5-6 eslabones, dicho R5 está opcionalmente sustituido por R10; R6 y R7 son en cada caso con independencia H o alquilo C1-3, opcionalmente sustituido por halogeno, oxo o -NR11R12; o R6 y R7 junto con el átomo al que están unidos forman con independencia un heterociclilo de 3-6 eslabones, opcionalmente sustituido por halogeno, oxo, -NR11R12 o alquilo C1-3; R8 y R9 son en cada caso con independencia H, alquilo C1-3, cicloalquilo C3-6, fenilo, heterociclilo de 3-6 eslabones o heteroarilo de 5-6 eslabones, opcionalmente sustituido por R10; o R8 y R9 junto con el átomo al que están unidos forman con independencia un heterociclilo de 3-6 eslabones, opcionalmente sustituido por halogeno, oxo, -NR11R12 o alquilo C1-3; R10 es con independencia H, oxo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, -(alquilo C0-3)CN, -(alquilo C0-3)OR11, -(alquilo C0-3)SR11, -(alquilo C0-3)NR11R12, -(alquilo C0-3)CF3, -(alquilo C0-3)NO2, -(alquilo C0-3)C(O)R11, -(alquilo C0-3)C(O)ORH, -(alquilo C0-3)-C(O)NR11R12, -(alquilo C0-3)NR11C(O)R12, -(alquilo C0-3)-S(O)1-2R11, -(alquilo C0-3)NR11S(O)1-2R12, -(alquilo C0-3)-S(O)1-2NR11R12, -(alquilo C0-3) (ciclo-alquilo C3-6) , -(alquilo C0-3)(heterociclilo de 3-6 eslabones), -(alquilo C0-3)C(O)-(heterociclilo de 3-6 eslabones), -(alquilo C0-3) (heteroarilo de 5-6 eslabones) o -(alquilo C0-3)fenilo, dicho R10 está opcionalmente sustituido con independencia por halogeno, alquilo C1-3, oxo, -CF3, -(alquilo C0-3)OR13, -(alquilo C0-3)NR13R14, -(alquilo C0-3)C(O)R13 o -(alquilo C0-3)S(O)1-2R13; R11 y R12 son con independencia H, alquilo C1-6, -(alquilo C0-3) (cicloalquilo C3-6) , -(alquilo C0-3) -(heterociclilo de 3-6 eslabones), -(alquilo C0-3) (heteroarilo de 5-6 eslabones) o -(alquilo C0-3)fenilo, opcionalmente sustituido por halogeno, oxo, -OR13, -SR13, -NR13R14, alquilo C1-3, -(alquilo C0-3) (cicloalquilo C3-6), -(alquilo C0-3)-fenilo, -(alquilo C0-3) (heterociclilo de 3-6 eslabones) o -(alquilo C0-3)(heteroarilo de 5-6 eslabones); o R11 y R12 junto con el átomo al que están unidos forman un heterociclilo de 3-6 eslabones, opcionalmente sustituido por halogeno, oxo, -NR13R14 o alquilo C1-3; R13 y R14 son con independencia H, alquilo C1-6, OH u OCH3, opcionalmente sustituido por halogeno, -NH2, -N(CH3)2, fenilo u oxo, dicho fenilo está opcionalmente sustituido por halogeno, alquilo C1-6, CF3, -NRaRb u ORa; o R13 y R14 junto al átomo al que están unidos forman un heterociclilo de 3-6 eslabones, opcionalmente sustituido por halogeno, oxo, -NH2, -N(CH3)2 o alquilo C1-3; R15 es con independencia H, halogeno, alquilo C1-3, alquenilo C1-3, alquinilo C1-3, cicloalquilo C3-4, -CF3, -ORa, -SRa, -CN, -NO2, -NRaSO2Rb, -NRaC(O)Rb o -NRaRb; Ra y Rb son con independencia H o alquilo C1-6 opcionalmente sustituido por halogeno u oxo; o Ra y Rb junto al átomo al que están unidos forman un heterociclilo de 3-6 eslabones, opcionalmente sustituido por halogeno, oxo o alquilo C1-3; con las condiciones siguientes: si R4 es -OH, R5 está ausente, y uno de B y D es N y el otro es CH, entonces la porcion de la formula 1 que tiene la estructura: (2), es diferente de (3) si la porcion de la formula 1 que tiene la estructura: (4) es (5), entonces la porcion de la formula 1 que tiene la estructura: (2) es diferente de las siguientes: (6); si la porcion de la formula 1 que tiene la estructura: (4) es (7), entonces la porcion de la formula 1 que tiene la estructura: (2) es diferente de las siguientes: (8), si A es CR3, B y D son CH, o B es CH y D es N, un R1 es -CH3 y el otro R1 es H, R2 es H, R4 es H o Cl; R5 está ausente; R3 es diferente de la estructura: (9); si A es CR3, B y D son CH, un R1 es F y el otro R1 es H, R2 es H, R4 es H o Cl; R5 está ausente; R3 es diferente de 3-cloro-piridin-2-ilo; si A es CR3, B es N; D es CH, un R1 es -CH3 y el otro R1 es H; R2 y son H; R5 está ausente; R4 es diferente de OH; y si A es CR3, B es CH, D es N, R1 es Cl, R2 y R3 son H, R4 es -NH-, R5 es diferente de la estructura: (10), en las que la línea ondulada representa el punto de union a la formula 1.
ARP100102023A 2009-06-11 2010-06-09 Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas AR077033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18632209P 2009-06-11 2009-06-11

Publications (1)

Publication Number Publication Date
AR077033A1 true AR077033A1 (es) 2011-07-27

Family

ID=42313557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102023A AR077033A1 (es) 2009-06-11 2010-06-09 Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas

Country Status (14)

Country Link
US (1) US8486950B2 (es)
EP (1) EP2440529A1 (es)
JP (1) JP5763057B2 (es)
KR (1) KR101530117B1 (es)
CN (1) CN102459187B (es)
AR (1) AR077033A1 (es)
AU (1) AU2010258597B2 (es)
BR (1) BRPI1011129A2 (es)
CA (1) CA2764728A1 (es)
IL (1) IL216511A0 (es)
MX (1) MX2011012840A (es)
SG (1) SG176781A1 (es)
TW (1) TW201103904A (es)
WO (1) WO2010142752A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505262A (ja) * 2009-09-17 2013-02-14 バンダービルト ユニバーシティー ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
AU2011328139A1 (en) 2010-11-10 2013-04-04 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as LRRK2 modulators
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2013018695A1 (ja) 2011-07-29 2013-02-07 武田薬品工業株式会社 複素環化合物
JP6043290B2 (ja) 2011-09-22 2016-12-14 武田薬品工業株式会社 縮合複素環化合物
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
JPWO2013146963A1 (ja) 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
JP6267193B2 (ja) * 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
CN104507940B (zh) 2012-06-01 2017-01-25 武田药品工业株式会社 杂环化合物
EP2914592B1 (en) * 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
NZ710270A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
TW201444798A (zh) * 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EA201591881A1 (ru) 2013-03-28 2016-04-29 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
WO2014177524A1 (en) * 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2015016206A1 (ja) 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
US20160168132A1 (en) * 2013-07-31 2016-06-16 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
CA2925935A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
WO2015068856A1 (en) 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
TWI651329B (zh) 2013-12-13 2019-02-21 美商維泰克斯製藥公司 作為鈉通道調節劑之吡啶酮醯胺之前藥
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
US10179790B2 (en) * 2014-06-04 2019-01-15 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2016199943A1 (en) 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
CN108026088B (zh) 2015-07-17 2021-02-12 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
WO2018030550A1 (en) 2016-08-09 2018-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds with an ror(gamma)t modulating activity
CN110520412A (zh) 2017-02-15 2019-11-29 南洋理工大学 用于治疗结核病的化合物
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
WO2020117877A1 (en) * 2018-12-04 2020-06-11 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
JP7407196B2 (ja) * 2018-12-20 2023-12-28 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP2023504546A (ja) 2019-12-06 2023-02-03 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021209377A1 (en) * 2020-04-16 2021-10-21 Basf Se A process for the preparation of 4-cyanobenzoyl chlorides
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022063140A1 (en) * 2020-09-23 2022-03-31 Shenzhen Ionova Life Science Co., Ltd. Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317534A (en) 1963-10-30 1967-05-02 Chugai Pharmaceutical Co Ltd Benzamidopyrimidines
JPS62158252A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンベンズアミド誘導体
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ES2176251T3 (es) * 1993-07-28 2002-12-01 Aventis Pharma Ltd Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP3122469B2 (ja) * 1995-06-06 2001-01-09 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病剤としてのピリジンイミニル−１，２−ベイゾイソオキサゾール類及び−ベンゾイソチアゾール類
JPH111456A (ja) * 1997-06-13 1999-01-06 Otsuka Pharmaceut Co Ltd アミド誘導体
US6562844B2 (en) * 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
CN1460097A (zh) * 2001-03-27 2003-12-03 第一三得利制药株式会社 以取代的苯甲酸衍生物为有效成分的NF－κB抑制剂
JP2003073357A (ja) * 2001-09-03 2003-03-12 Mitsubishi Pharma Corp アミド化合物を含有するＲｈｏキナーゼ阻害剤
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US7338950B2 (en) 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
GB0403635D0 (en) * 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CN101080392B (zh) 2004-12-16 2010-05-05 霍夫曼-拉罗奇有限公司 作为抗肥胖药剂的哌嗪基吡啶衍生物
DE602005013819D1 (de) 2004-12-22 2009-05-20 Astrazeneca Ab Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel
EP1863794A2 (en) 2005-03-16 2007-12-12 Targegen, Inc. Pyrimidine compounds and methods of use
DE102005060449A1 (de) 2005-12-17 2007-06-21 Bayer Cropscience Ag Carboxamide
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
MX2008016423A (es) * 2006-06-29 2009-01-22 Hoffmann La Roche Arilamidas sustituidas con tetrazol.
ES2428874T3 (es) 2006-08-09 2013-11-12 Basilea Pharmaceutica Ag Nuevos macrólidos útiles contra las enfermedades inflamatorias y alérgicas
WO2008044700A1 (fr) * 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
SI2343286T1 (sl) 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2008153974A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.

Also Published As

Publication number Publication date
JP2012529470A (ja) 2012-11-22
WO2010142752A1 (en) 2010-12-16
AU2010258597A1 (en) 2011-12-15
IL216511A0 (en) 2012-02-29
TW201103904A (en) 2011-02-01
CA2764728A1 (en) 2010-12-16
EP2440529A1 (en) 2012-04-18
CN102459187A (zh) 2012-05-16
SG176781A1 (en) 2012-01-30
US20100317643A1 (en) 2010-12-16
KR20120034729A (ko) 2012-04-12
MX2011012840A (es) 2012-01-27
JP5763057B2 (ja) 2015-08-12
CN102459187B (zh) 2015-06-17
KR101530117B1 (ko) 2015-06-18
US8486950B2 (en) 2013-07-16
BRPI1011129A2 (pt) 2016-11-01
AU2010258597B2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
AR077033A1 (es) Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
CO2020006411A2 (es) Inhibidores de endonucleasa cap-dependientes
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
CO6220855A2 (es) Compuesto a base de 54 -fenil-6-(2,2,2-trifluoro-1-feniletoxi)pirimidina y metodos para su empleo
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR064010A1 (es) Inhibidores de la actividad de la akt
AR051293A1 (es) Inhibidores bace
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR053778A1 (es) Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa
AR081577A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR057982A1 (es) Compuestos de [hetero) arilo con actividad antagonista de mch y composicion farmaceutica que comprende estos compuestos
AR051195A1 (es) Piridinas como inhibidores de plk
PE20091100A1 (es) Nuevos compuestos 010
AR069524A1 (es) Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
AR057980A1 (es) Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica
AR079130A1 (es) Compuestos inhibidores de la hepatitis c
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR067058A1 (es) Oxazolidinonas sustituidas y su uso para preparar medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure